BACKGROUND: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for 2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years. RESULTS: The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. CONCLUSIONS: Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25.
INTRODUCTION
High-dose chemotherapy followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard treatment for medically fit patients with relapsed or refractory aggressive lymphomas. 1, 2 Reported survival rates 3 to 5 years after auto-HCT for classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) range from 40% to 70%. [2] [3] [4] [5] [6] [7] [8] Treatment failure is most commonly due to relapse or progression of the underlying disease, which primarily occurs within the first 2 years after auto-HCT. 1 For those patients who survive the initial post-auto-HCT period, long-term outcomes are not well described.
Prior reports of long-term outcomes after auto-HCT were limited by short follow-up times, the inclusion of patients who received older therapies, or small, nonrepresentative patient cohorts. The first major study of late mortality described outcomes of 854 patients who survived at least 2 years after auto-HCT for leukemia or lymphoma between 1981 and 1998. 9 With a median followup of 7.6 years and with 68% having received total body irradiation (TBI)-based preparative regimens, the cohort had a 13-fold increased risk of late death in comparison with the general population. Subsequent reports have confirmed an increased risk of late mortality. [10] [11] [12] [13] In addition, mostly single-center studies have reported high rates of organ impairment, functional limitations, and subsequent malignant neoplasms (SMNs) in auto-HCT survivors. [13] [14] [15] To address the gaps in the literature, we selected a representative, multicenter cohort of 2-year disease-free survivors of auto-HCT for cHL or DLBCL who were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to evaluate 1) long-term survival and mortality risk in comparison with the general population, 2) SMNs, 3) nonmalignant late effects, and 4) predictive factors for worse long-term outcomes. Because cHL is the most common cancer in adolescents and young adults (AYAs), we also conducted a subanalysis of AYA survivors. 16 
MATERIALS AND METHODS

Data Source
The CIBMTR is a voluntary working group composed of more than 450 transplantation centers worldwide that contribute detailed hematopoietic cell transplant data to a statistical center at the Medical College of Wisconsin in Milwaukee and the National Marrow Donor Program in Minneapolis. Participating centers are required to report all transplants consecutively; compliance is monitored by onsite audits. Patients are followed longitudinally. Computerized checks for discrepancies, physician reviews of submitted data, and onsite audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants and are under the guidance of the institutional review board of the National Marrow Donor Program.
The CIBMTR collects transplant-essential data for all patients, which include the following: demographics, disease type and stage, pretransplant chemotherapy, graft type, preparative regimen, development of a new malignancy, survival, relapse, and cause of death. A subset of patients, selected by a weighted randomization scheme, also have comprehensive research level data collected. Late effects data are obtained from this subset; therefore, only this group of patients was included in the current study. The presence of the following specific late effects is reported: avascular necrosis, bronchiolitis obliterans, pulmonary hemorrhage, cataracts, congestive heart failure, myocardial infarction, diabetes/hyperglycemia, gonadal dysfunction/infertility requiring hormone replacement, growth hormone deficiency/growth disturbance, hypothyroidism, hemorrhagic cystitis/hematuria requiring medical intervention, noninfectious liver toxicity, pancreatitis, posttransplant microangiopathy/thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, renal failure, and stroke/seizure. The data are collected before transplantation, 100 days and 6 months after transplantation, and then annually.
To confirm diagnoses of SMNs, pathology reports were obtained from reporting transplant centers. Any new malignancy diagnosis that could not be confirmed on central review was not included in the analysis.
Study Population
The study population consisted of AYAs and older adults (age > 39 years) who had survived progression-free for 2 years after auto-HCT for cHL or DLBCL between January 1, 1990, and December 31, 2008. Patients aged 15 to 39 years were characterized as AYAs on the basis of the National Cancer Institute's definition. 17 The study was restricted to patients treated in the United States and Canada.
There were 5171 patients undergoing auto-HCT for the first time for cHL or DLBCL at an age 15 years, and 1023 were excluded on the basis of their transplant center's location or completeness of follow-up. Another 2250 patients were excluded because of death (n 5 1594), relapse (n 5 584), or loss to follow-up (n 5 72) within 2 years of auto-HCT. Other exclusion criteria were nodular lymphocyte predominant Hodgkin lymphoma (n 5 5), low-grade lymphoma or chronic lymphocytic leukemia transforming to DLBCL (n 5 102), a known human immunodeficiency virus-positive status (n 5 53), subsequent transplantation within 2 years of the first transplant (n 5 52), a pre-auto-HCT history of another malignancy (other than nonmelanomatous skin cancers; n 5 56), and missing CIBMTR forms (n 5 13). The final study cohort consisted of 1617 patients from 134 centers.
Outcomes
The studied outcomes included overall survival (OS), progression-free survival (PFS), relapse, and nonrelapse mortality (NRM). OS was defined as the time to death from any cause and was censored at the last point of contact. For PFS, a patient was considered a treatment failure at the time of progression/relapse or death from any cause. Relapse was defined as progressive disease after auto-HCT or disease recurrence after a complete remission; death in remission was considered a competing risk. NRM was defined as death without evidence of progression/relapse; relapse was considered a competing risk.
Additional outcomes included the development of SMNs and nonmalignant organ impairments 2 years after auto-HCT. Late effects were censored at the time of a second transplant or relapse. Only the specific organ impairments collected on the CIBMTR forms described previously were analyzed.
Statistical Analysis
Descriptive statistics were calculated for patient demographic and disease-and treatment-related variables. The Kaplan-Meier method was used to estimate the probability of OS, which was calculated from the 2-year landmark after auto-HCT to the date of death or last follow-up. The cumulative incidence function was used to estimate relapse, relapse-related death, and NRM. The frequencies of individual late effects (censored at relapse or second transplant) were calculated. In addition, the cumulative incidence of developing an SMN, 1 or more nonmalignant late effects, or 2 or more late effects was estimated. Standardized mortality ratios (SMR) were used to analyze the ratio of observed deaths in the study population to expected deaths in country-, age-, race-, and sex-matched controls from the general population in the United States and Canada. General population data were obtained from the National Center for Health Statistics.
Cox proportional hazards analysis was used to identify multivariate risk factors for overall mortality, NRM, SMNs, and 1 or more late effects. The stepwise selection method with a significance level of .05 was used to identify multivariate risk factors. The proportional hazards assumption was checked. If violated, it was included as a time-dependent covariate. Pairwise interactions between significant variables was examined. Separate models were created for patients with Hodgkin lymphoma and those with DLBCL.
The AYA subanalysis used the same methodology that the main analysis used. Analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Patient and Transplant Characteristics
The characteristics of the study population are presented in Table 1 . Of the 1617 patients eligible for analysis, 836 had cHL, and 781 had DLBCL. The median duration of follow-up was 127 months (range, 24-292 months) after auto-HCT. For patients with cHL, the median age at auto-HCT was 33 years; 72% (n 5 606) were included in the AYA group. Forty-four percent (n 5 371) received radiation therapy before auto-HCT conditioning, and 5% (n 5 39) received a TBI-based preparative regimen.
For patients with DLBCL, the median age at auto-HCT was 51 years; 25% (n 5 192) were included in the AYA group. Twenty-eight percent (n 5 218) received radiation therapy before conditioning, and 15% (n 5 115) received a TBI-based preparative regimen. Figure 1 displays the Kaplan-Meier estimates and cumulative incidences of survival outcomes. Among 2-year survivors of auto-HCT for cHL, the OS rates 3 and 5 years after auto-HCT were 96% (95% confidence interval [CI], 95%-98%) and 90% (95% CI, 87%-92%), respectively. The PFS rates at 3 and 5 years were 93% (95% CI, 91%-95%) and 84% (95% CI, 81%-86%), respectively. The cumulative incidence of relapse was 4% (95% CI, 3%-6%) 3 years after auto-HCT and 9% (95% CI, 8%-12%) 5 years after auto-HCT. The incidence of NRM was 3% (95% CI, 2%-4%) at 3 years and 7% (95% CI, 5%-9%) at 5 years.
Survival and Relapse Outcomes
Among the 256 patients with cHL who died more than 2 years after auto-HCT, relapse accounted for 44% of the deaths (n 5 113), and NRM accounted for 56% of the deaths (n 5 143). The causes of NRM are presented in Table 2 . Of the 173 patients who died more than 5 years after auto-HCT, relapse accounted for 28% of the deaths (n 5 49), and NRM accounted for 72% of the deaths (n 5 124). The SMR was 9.6 (95% CI, 8.1-11.2) for 2-year cHL survivors versus the general population. Among 2-year survivors of auto-HCT for DLBCL, the OS rates 3 and 5 years after auto-HCT were 95% (95% CI, 93%-96%) and 89% (95% CI, 87%-91%), respectively. The PFS rates at 3 and 5 years were 91% (95% CI, 89%-93%) and 82% (95% CI, 79%-85%), respectively. The cumulative incidence of relapse was 4% (95% CI, 3%-6%) 3 years after auto-HCT and 7% (95% CI, 6%-9%) 5 years after auto-HCT. The incidence of NRM was 4% (95% CI, 3%-6%) at 3 years and 7% (95% CI, 6%-9%) at 5 years.
Among the 223 patients with DLBCL who died more than 2 years after auto-HCT, relapse accounted for 43% of the deaths (n 5 96), and NRM accounted for 57% of the deaths (n 5 127). The causes of NRM are presented in Table 2 . Of the 142 patients who died more than 5 years after auto-HCT, relapse accounted for 29% of the deaths (n 5 41), and NRM accounted for 71% of the deaths (n 5 101). The SMR was 3.4 (95% CI, 2.9-4.1) for 2-year DLBCL survivors versus the general population. Table 3 displays the multivariate models of overall mortality and NRM in patients with cHL. Risk factors for overall mortality included older age (P < .001), male sex (P 5 .039), a Karnofsky score < 90% at the time of auto-HCT (P 5 .011), TBI exposure (P < .001), and a higher number of lines of chemotherapy before auto-HCT (P 5 .015). Predictors of NRM included older age (P < .0001), a Karnofsky score < 90% at the time of auto-HCT (P 5 .011), and TBI exposure (P < .0001). Table 4 displays the multivariate models of overall mortality and NRM in patients with DLBCL. Risk factors for overall mortality included older age (P < .001) and TBI exposure (P 5 .013). Predictors of NRM were also older age (P < .0001) and TBI exposure (P 5 .043).
Predictors of Mortality
Nonmalignant Late Effects
At least 1 nonmalignant late effect was reported in 9% of the patients (n 5 148). Two or more late effects were reported in 2% of the patients (n 5 30).
The incidences of specific late effects are described in Table 5 . The most frequently reported nonmalignant late effects were endocrine impairments, including hypothyroidism (n 5 50), diabetes (n 5 23), and gonadal dysfunction (n 5 16). Cataracts (n 5 16) and cardiac impairments, including congestive heart failure (n 5 14) and myocardial infarction (n 5 11), were the next most commonly reported late effects. Other complications that were reported in 10 or more patients included interstitial pneumonitis/idiopathic pneumonia syndrome (n 5 12) and stroke/seizures (n 5 10). (22) 39 (17) Abbreviations: cHL, classic Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; SMN, subsequent malignant neoplasm.
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Cancer February 15, 2018 (n 5 6), acute myeloid leukemia (n 5 5), gastrointestinal cancer (n 5 5), and breast cancer (n 5 5). Predictors of SMNs included older age (P < .001) and a higher number of lines of chemotherapy (P 5 .015; Table 6 ). Among patients with DLBCL, biopsy-documented SMNs included myelodysplastic/myeloproliferative syndrome (n 5 24), gastrointestinal cancer (n 5 7), genitourinary tract cancers (n 5 7), acute myeloid leukemia (n 5 5), and breast cancer (n 5 5). Older age (P < .001) was the only risk factor identified for SMNs in patients with DLBCL (Table 6 ).
AYA Subanalysis
The outcomes of the AYA subpopulation largely mirrored the outcomes of the overall population. For cHL, the OS rate was 91% (95% CI, 88%-93%), the NRM rate was 7% (95% CI, 5%-9%), and the relapse rate was 8% (95% CI, 6%-10%) 5 years after auto-HCT. For DLBCL, the OS rate was 97% (95% CI, 94%-99%), the NRM rate was 2% (95% CI, 1%-5%), and the relapse rate was 5% (95% CI, 2%-8%) 5 years after auto-HCT.
Relapse accounted for 47% of the deaths among patients with cHL and 31% of the deaths among patients with DLBCL. At least 1 nonmalignant late effect was reported in 8% of the patients; 2 or more late effects were reported in 1% of the patients. A total of 30 SMNs were reported: 25 in patients with cHL and 5 in patients with DLBCL.
For patients with cHL, predictors of overall mortality included a Karnofsky score < 90 (P 5 .0004), a higher number of lines of chemotherapy (P < .0001), and TBI exposure (P < .0001). Risk factors for NRM included a Karnofsky score < 90 (P < .0001) and TBI exposure (P 5 .0003). For patients with DLBCL, TBI exposure (P 5 .011) was predictive of late mortality. No significant risk factors were identified for NRM.
DISCUSSION
We present the major long-term outcomes, including survival, SMNs, and late effects, for a multicenter cohort of 2-year auto-HCT survivors of cHL or DLBCL (n 5 1617) treated in a modern era of therapies and reported to the CIBMTR. We found that patients who survived progression-free for 2 years after auto-HCT had favorable long-term survival. Five years after auto-HCT, the OS rate was 90% among patients with cHL and 89% among patients with DLBCL. Despite favorable survival outcomes, however, patients with cHL had a 9.6-fold increased risk of late mortality and patients with DLBCL had a 3.4-fold increased risk of late mortality in comparison with an age-and sex-matched general population. Relapse of the primary disease continued to be a major cause of late mortality and accounted for 44% of the deaths among patients with cHL and 43% of the deaths among patients with DLBCL. We report a myriad of SMNs and nonmalignant late effects experienced by survivors. By adjusted analyses, we found that the most consistent risk factors for worse long-term outcomes were TBI exposure and older age at the time of auto-HCT.
The strengths of the study are the representative patient cohort and the long follow-up time. The 1617 patients were reported to the CIBMTR from 134 centers in the United States and Canada, and these centers represent a range of community and tertiary-care centers from both rural and urban regions. The median follow-up time was 10.6 years, which was longer than the follow-up times of comparable studies and allowed a more thorough assessment of mortality and late effects. 9, 10, 14, 18 To focus on treatment-related toxicities of auto-HCT, the study population was chosen to represent patients most likely to be cured by transplantation, namely, patients with the 2 most common aggressive lymphomas, cHL and de novo DLBCL. Even though we selected for patients who survived progression-free for 2 years after transplantation, relapse remained a major cause of late mortality. Relapse accounted for 44% of deaths among 2-year survivors and 29% of deaths among 5-year survivors. In agreement with our findings, previous reports have also found relapse to be a leading cause of late deaths among patients who survive the initial post-auto-HCT period. 9, 10, 13, 18 This observation highlights the importance of posttransplant relapse prevention. In this respect, brentuximab vedotin was recently approved as posttransplant consolidation therapy for certain high-risk patients with cHL. 19 For DLBCL, although rituximab maintenance was not shown to improve posttransplant disease control, the recently activated Blood and Marrow Transplant Clinical Trials Network Protocol 1201 (Alliance A051301) will examine the role of ibrutinib in activated B cell-type DLBCL. 20 Other agents that warrant investigation as posttransplant relapse prevention strategies include checkpoint inhibitors, immunomodulators, and PI3K inhibitors. Nevertheless, the majority of 2-and 5-year survivors in the current study did not die because of relapse of their underlying lymphoma. For these patients, the patterns and risk factors for treatmentrelated morbidity and mortality are most informative.
Similarly to the other large series of long-term outcomes after auto-HCT for lymphoma, our study found relatively high rates of SMNs. 9, 18 This was true despite the lower use of TBI-containing preparative regimens in comparison with other, less contemporary studies. The development of SMNs is an unfortunate yet inherent late effect of the administration of myeloablative therapy. When we are questioning ways to minimize this risk, perhaps the most important modifiable risk factor identified in this study for impaired OS and SMNs is the use of TBI. Other reports of SMNs after auto-HCT for lymphoma did not identify risk factors for the development of SMNs. 9, 13, 15, 18 There are, however, conflicting reports about the association of TBI and long-term survival after auto-HCT. Worse PFS has been described for patients who have received TBI. 18 In contrast, Bhatia et al's large report 9 found that TBI provided a protective effect such that the risk of late death was 2-fold higher among patients who did not receive TBI versus those who did. It should be noted that the study captured patients with a range of hematologic malignancies between 1981 and 1998; thus, it is difficult to compare those TBI findings with the findings of the current study.
Our study reported a low incidence of nonmalignant late effects; 9% of the cohort had at least 1 late effect that occurred at least 2 years after auto-HCT, and 2% had multiple late effects. Data on late effects after auto-HCT for lymphoma are limited, but the few available studies found late effects in the majority of survivors. The largest series reported outcomes of 458 patients who were part of the Bone Marrow Transplant Survivor Study (BMTSS). 21 Of the survivors, 60.7% reported at least 1 nonmalignant late effect. Notably, data were collected via self-report, and the study included patients with different types of hematologic malignancies. A separate analysis that included only patients from the BMTSS cohort who had undergone auto-HCT for lymphoma (n 5 276) also reported high incidences of late effects.
14 For instance, 33%, 23%, and 22% of the study population had neurosensory, endocrine, and cardiopulmonary impairments, respectively. The differences in outcomes between the BMTSS analysis and our study would not be explained by differences in the follow-up time because the BMTSS analysis had a median follow-up time of 6 years, whereas our study had a median follow-up time of 10 years. Because the patients in the BMTSS analysis were treated between 1974 and 1998, the majority (69%) received a TBI-based conditioning regimen. This is in contrast to the few patients in the current study treated with TBIbased regimens and may, in part, account for the differences in late effects findings. It is also important to acknowledge that CIBMTR data forms capture a limited number of late effects, and screening practices for late effects are not consistent among centers. Therefore, the low incidence of late morbidities in our sample was likely an underrepresentation of the patients' true symptom burden. Our results, in combination with prior data, support the need for continued long-term follow-up of patients after auto-HCT to screen for late effects. 22 The current study has some limitations that should be considered when we are interpreting the results. It used a retrospective cohort design, and specific drug and radiation dosing data were not available. As explained previously, only select late effects data were collected. Furthermore, auto-HCT patients are often followed by their transplant centers only for a short time after transplantation. Therefore, it can be challenging for centers to ascertain long-term follow-up information, and this leads to missing data. In addition, we required original biopsy reports to confirm SMNs, but we were unable to obtain reports from several centers. Hence, we may have underestimated the true incidence of SMNs. Although we had a median follow-up time of 10.6 years, it is possible that a longer follow-up time would reveal a larger burden of late effects.
In summary, we found that patients who survived progression-free for at least 2 years after auto-HCT for cHL or DLBCL had favorable long-term outcomes. Five years after auto-HCT, 90% of the 2-year cHL survivors were alive, and 89% of the 2-year DLBCL survivors were alive. Survivors, however, continue to be at excess risk for late mortality in comparison with the general population because of relapse, SMNs, and other late effects. Our results affirm the need to build therapies to augment the efficacy of auto-HCT and to treat relapse after auto-HCT. As outcomes continue to improve, our study highlights the importance of close, systematic follow-up of auto-HCT patients to screen for and treat late effects.
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